Delivery Order SPE2DR25D3201-SPE2DR26FT4KD
- Not listed
- The Defense Logistics Agency awarded a $11,686.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits, with an ultimate completion date of June 2, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $2,337.32 to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits on September 12, 2025, with completion expected by September 15, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,530.76 to AmerisourceBergen Drug Corp for Neulasta Onpro 6 mg/0.6 ml kits on September 9, 2025, with completion scheduled for September 10, 2025. The award utilized firm fixed pricing with no set-aside designation, indicating competitive selection among eligible contractors. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate...
- The Defense Logistics Agency awarded a $43,815.44 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Neulasta OnPro 6 mg/0.6 mL kits. The contract represents a firm fixed price, non-competitive set-aside award with an ultimate completion date of April 25, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $2,337.32 to AmerisourceBergen Drug Corp for Neulasta Onpro 6 mg/0.6 ml kits, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of DLA pharmaceutical procurements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical supply needs,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,389.54 to AmerisourceBergen Drug Corp for the supply of Neulasta Onpro 6 mg/0.6 ml injectable kits, with an ultimate completion date of December 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $10,026.36 for Neulasta 6 mg/0.6 mL syringes, with completion targeted for August 7, 2025. The contract, issued on August 6, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- This is a $2,465.76 firm-fixed price delivery order awarded to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of Neulasta OnPro 6 mg/0.6 ml kits. The order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support the Department of Defense's global military treatment programs and...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,831.39, is for the delivery of NEULASTA ONPRO 6 MG/0.6 ML KIT 0.6ML, a specialty medication. This contract does not have a set-aside designation, indicating it was competed openly. AmerisourceBergen is the prime contractor, and the contract has an ultimate completion date of...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,729.49, is for the supply of Neulasta OnPro 6 mg/0.6 ml kits to support federal healthcare programs, particularly military and veterans' healthcare systems. The contract has an ultimate completion date of February 4, 2025. AmerisourceBergen holds a significant Indefinite...
- SPE2DR25D3201Indefinite Delivery Contract
- SPE2DR25D3201-SPE2DR26FT4KDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,231.59 to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits on December 2, 2025, with completion scheduled for December 3, 2025. This firm fixed-price, non-set-aside delivery order represents a pharmaceutical supply transaction under a competitively awarded contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary pharmaceutical distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military and veteran healthcare systems. Neulasta, a specialty oncology medication used for chemotherapy-related side effects, exemplifies the company's role in delivering specialized pharmaceutical products across multiple therapeutic domains to support Defense Health Agency and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 12/1/25 |